Oramed Pharmaceuticals (NASDAQ:ORMP) Announces Quarterly Earnings Results

Oramed Pharmaceuticals (NASDAQ:ORMP) issued its quarterly earnings results on Thursday. The biotechnology company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.04, Zacks reports.

Oramed Pharmaceuticals Stock Performance

Shares of ORMP traded down $0.09 during trading hours on Friday, hitting $2.21. The stock had a trading volume of 74,075 shares, compared to its average volume of 157,620. The firm has a market cap of $89.09 million, a P/E ratio of 20.09 and a beta of 1.61. The company’s fifty day simple moving average is $2.30 and its 200 day simple moving average is $2.35. Oramed Pharmaceuticals has a 12-month low of $1.96 and a 12-month high of $3.14.

Analyst Upgrades and Downgrades

Separately, StockNews.com lowered Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, February 19th.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.